A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)

Trial Profile

A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs APL 2 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FILLY
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 20 Oct 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Aug 2017.
    • 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top